Donate
News

News

98% Report No Serious Events: Phase 1 Trial Risks for US Participants

October 1, 2026

98% Report No Serious Events: Phase 1 Trial Risks for US Participants

Participant discussing trial consent with clinician

Most people who join a phase 1 trial experience mild or moderate side effects, and a systematic review of 475 trials found that more than 98% of participants reported no serious adverse events tied to the study drug. Severe, life-threatening reactions are rare in the published data, but rare does not mean impossible, especially in first-in-human studies where the unknowns are greatest. Your own risk depends heavily on the specific drug, the protocol’s safeguards, and your health. We break down what the numbers mean and what to ask before you say yes.

TL;DR:

  • Serious adverse events are rare in phase 1 trials, with the systematic review reporting no related events in over 98% of cases among 27,185 participants.
  • Most common side effects include fatigue, nausea, injection-site pain, mild fever, skin irritation, and temporary lab value changes, usually occurring within hours to days.
  • The risk of severe or fatal outcomes remains very low, averaging about 1.66 severe events per 1,000 participant-days in healthy volunteer trials, but specific risks vary by drug and patient health.
  • Cellular and gene therapies carry unique risks such as cytokine release syndrome and delayed effects, requiring extended monitoring and dedicated safety protocols.
  • Trial safeguards like conservative starting doses, cohort escalation, stopping rules, independent oversight, and thorough informed consent procedures help minimize individual risk.
Hcrfwingstocure
Support New Cancer Research
Your support helps fund out of the box cancer research at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center.
Support cancer research

Table of Contents

What a phase 1 trial is and who typically enrolls

A phase 1 trial exists to answer one question before any other: is this safe enough, and at what dose, to move forward? Researchers watch closely for how the body absorbs, breaks down, and clears a new treatment, known as pharmacokinetics and pharmacodynamics, while tracking side effects at each dose level. Effectiveness is a secondary hope at this stage, not the primary goal.

The people who enroll differ sharply depending on the disease being studied. Trials for new drugs in generally healthy conditions often recruit healthy volunteers, since researchers want a clean baseline free of other illnesses. Oncology phase 1 trials work differently: participants are typically patients who have exhausted standard treatment options, and many cancer phase 1 studies enroll roughly 15 to 30 people, though the exact number depends on the drug’s design and how many dose levels need testing.

That distinction shapes what “risk” even means in each setting. A healthy volunteer taking on risk with no direct medical benefit is a very different calculation than a cancer patient weighing a phase 1 drug against limited remaining options. Enrollment criteria also narrow the picture of who ends up in the data. Sicker or more medically complex candidates are frequently excluded from early trials specifically because their added vulnerability could obscure whether side effects come from the drug or from their underlying condition. That filtering effect matters when you read published safety statistics: the population studied is not a random cross section of everyone who might one day take the drug. Understanding how clinical trial phases build on each other helps put phase 1 data in context before you look at phase 2 or 3 results.

What a phase 1 trial is and who typically enrolls — overview diagram

For most participants, the lived experience of a phase 1 trial is closer to a rough week than a medical emergency. The symptoms below show up often enough that trial staff plan for them as a matter of course.

  • Fatigue and general malaise, often the most frequently reported complaint across drug classes.
  • Nausea or gastrointestinal upset, sometimes tied to dosing schedule or food timing.
  • Injection-site pain, redness, or swelling for infused or injected therapies.
  • Low-grade fever or flu-like symptoms, especially with immune-modulating drugs.
  • Mild rash or skin irritation.
  • Lab value changes, such as shifts in liver enzymes or blood counts, caught through routine testing rather than felt symptoms.

Procedures themselves carry their own smaller risks separate from the drug being tested. Repeated blood draws can cause bruising or, rarely, vein irritation. Biopsies carry a modest risk of bleeding or infection at the site. Imaging scans involving contrast dye occasionally trigger allergic reactions, and infusion appointments carry a chance of reactions at the IV site or, less often, a systemic response during the infusion itself.

Most expected side effects appear within the first hours to days after a dose, which is exactly why early phase 1 visits tend to be longer and more frequent than later ones. Sites draw labs, check vital signs, and sometimes monitor with an ECG at scheduled intervals so that a mild reaction gets caught and treated before it becomes anything worse.

Pro Tip: Ask the study team in advance what the “typical” side-effect timeline looks like for the specific drug you’re considering, not just the general list in the consent form.

Severe, rare, and catastrophic risks: evidence and limits

This is the part prospective participants most want quantified, and the honest answer is that severe outcomes are uncommon but not zero. The most detailed evidence comes from a systematic review of phase 1 trials involving healthy participants, covering 475 trials and 27,185 people.

The vast majority of the 475 reviewed trials reported no serious adverse events judged related to the study drug, and five deaths occurred across the entire dataset, none of them attributed to the investigational drug itself. In trials where severe events did occur, the median rate was about 1.66 severe events per 1,000 participants per adverse-event monitoring day, a rate low enough that most individual trials see none at all.

Oncology phase 1 trials tell a related but distinct story, because participants there are already living with serious illness. An NCI analysis found that treatment-related death in phase 1 solid-tumor cancer trials has remained very low even as tumor response rates improved over two decades, rising from a historical 4% to 5% range as targeted therapies and better supportive care changed the landscape. The same analysis noted that older, sicker patients and those with liver problems showed somewhat higher risk, a reminder that population-level statistics describe an average, not a guarantee for any one person.

A few caveats matter here:

  • Publication bias can skew what gets published toward more favorable safety outcomes, since neutral or negative trials are less consistently reported.
  • Trial heterogeneity means a systematic review’s average rate blends drugs with wildly different mechanisms and risk profiles into one number.
  • Population-level estimates cannot predict an individual outcome, since your specific health status, the specific drug class, and the specific protocol all shift the real risk you face.

Reading a trial’s own reported results with these limits in mind, rather than treating any single percentage as destiny, is part of what it means to turn published data into a realistic personal risk assessment.

Specialized risks for cellular, gene, and immunotherapy trials

Cellular therapies, gene therapies, and certain immunotherapies do not follow the same risk pattern as a small-molecule pill, and regulators treat them differently for that reason. The FDA’s guidance for cellular and gene therapy products recognizes that these interventions can cause multi-organ effects, delayed malignancy risk, and prolonged biological activity that a conventional drug would not, since a modified cell or viral vector can persist and keep acting in the body long after a single dose.

That difference shows up in a handful of named, serious complications that trial teams specifically watch for:

  • Cytokine release syndrome, an overactive immune response that can range from fever to dangerously low blood pressure.
  • Neurotoxicity, seen with some CAR T-cell therapies, ranging from confusion to more severe neurological symptoms.
  • Insertional mutagenesis, a theoretical risk with some gene-therapy vectors, where inserted genetic material disrupts a nearby gene.
  • Delayed effects, since a living or genetically modified product can act on the body for years rather than clearing within days like a conventional drug.

Emerging therapy classes bring their own open questions too. Research on drug classes originally developed for other conditions, including some GLP-1 medications now being studied for anti-cancer potential, illustrates how a treatment’s safety profile in one context does not automatically apply to a new one, which is exactly why cellular and gene therapy trials require dedicated monitoring rather than a copy-paste safety plan from earlier drug trials.

If you are considering a cellular or gene therapy trial, ask specifically how long follow-up continues after your last dose, what immunology testing is built into the schedule, and what stopping rules exist if an infusion reaction starts.

Pro Tip: For any cell or gene therapy trial, ask what happens to monitoring and support if you need to move or change providers during the years-long follow-up period some of these products require.

How trials reduce risk through escalation, monitoring, and oversight

The reason phase 1 trials are not simply a leap of faith is that the design itself is built to catch problems early and stop before they compound. Several layers work together.

  1. Starting doses are set conservatively, typically calculated from animal safety data with a substantial safety margin built in before the first human ever receives the drug.
  2. Dosing proceeds in small groups, or cohorts, with a defined number of participants observed at each dose level before anyone moves to the next, higher dose.
  3. Stopping rules are written into the protocol in advance, specifying exactly what side effects, at what severity, pause or end dose escalation.
  4. Routine labs, vital signs, and often ECG monitoring are scheduled at defined intervals so that a problem shows up on paper before it becomes a crisis.
  5. An Institutional Review Board approves and continues to oversee the trial, reviewing the protocol’s ethics and participant protections before enrollment starts and throughout.
  6. The FDA reviews the sponsor’s Investigational New Drug application, evaluating nonclinical safety data and, for cellular and gene therapies, the manufacturing and product-characterization data that can be a source of unseen risk if the product itself is unstable.
  7. Independent data monitoring committees, when a protocol includes one, review accumulating safety data with no stake in the trial’s outcome and have the authority to recommend changes or a halt.

Ask who on the trial team has the authority to pause your dosing, and under what specific conditions, since that answer tells you how seriously the stopping rules are enforced in practice rather than just written on paper.

Informed consent is not a form you sign once and forget. FDA guidance treats it as an ongoing conversation, one that should continue with updates whenever new safety information emerges during the trial. Before you agree to enroll, work through this list with the study team.

  • Ask for the purpose and phase in plain language, along with a summary of prior animal or human data on the drug.
  • Ask what risks are foreseeable and which remain genuinely unknown, since honest uncertainty is part of what makes a trial.
  • Get a full list of procedures, including blood draws, biopsies, imaging, and infusions, with the time commitment each one requires.
  • Ask about contraception and reproductive guidance, since many early trials require pregnancy precautions for both participants and partners.
  • Confirm who pays for trial-related care, including treatment for a complication caused by the study itself.
  • Ask what compensation exists for research-related injury, and get the answer in writing if possible.
  • Confirm emergency contact procedures, withdrawal terms, and any follow-up obligations that continue after your participation ends.

Our guide to informed consent walks through each of these points in more depth, and questions about costs are covered further in our clinical trial insurance coverage resource.

Pro Tip: Bring a written list of your questions to the consent meeting and ask for written answers to anything the team cannot address on the spot.

How individual health factors change risk and eligibility

The same drug at the same dose does not carry identical risk for every participant, and trial teams build eligibility criteria around that reality. Age matters: older adults metabolize drugs differently and often carry more baseline health conditions, which the NCI’s analysis flagged as a factor in somewhat higher risk among older, sicker patients. Liver problems specifically were noted in that same analysis as a marker of elevated risk, since the liver is often responsible for clearing a drug from the body.

Organ function more broadly shapes eligibility. Reduced kidney or liver function can cause a drug to build up to unexpectedly high levels, and current medications can interact with the study drug in ways that are hard to predict without careful review. This is why screening visits exist before enrollment, not as a formality but as a genuine safety check.

If you have significant comorbidities, are on multiple medications, or have had prior serious reactions to related drug classes, it is worth asking for a more detailed individualized risk discussion before enrolling rather than relying on the general consent language. Our eligibility guide covers common exclusion criteria and what they tend to mean in practice. When in doubt, a second opinion from your treating clinician, someone who knows your full medical history, is worth the extra step before signing anything.

If a serious event happens: reporting, treatment, and long-term follow-up

Trials are required to have a clear chain of response when something goes wrong, and knowing that chain in advance can ease some of the anxiety around joining one. A serious adverse event is typically reported first by the site to the sponsor, and then, depending on severity, escalated to the FDA and the Institutional Review Board overseeing the trial. That reporting obligation exists specifically to catch patterns across participants that a single site might not notice on its own.

Immediate care for you as the participant should not wait on paperwork. Reputable protocols specify who provides treatment for a trial-related complication and how quickly.

  • Check the consent form for language specifying who is responsible for treating a trial-related injury, and whether that care is provided at no cost to you.
  • Ask whether compensation is offered for research-related injury, separate from any care itself.
  • Confirm what documentation you’ll receive if a serious event occurs, both for your own records and for any future care team.

Follow-up does not always end when your active participation does. This is especially true for cellular and gene therapy trials, where the FDA specifically recommends extended monitoring because effects can appear well after the treatment itself has been given. Withdrawing from a trial early is always your right, but ask what that means for any promised follow-up care or monitoring, since withdrawal terms vary by protocol and are worth understanding before you need them.

HCRF perspective and resources to help you decide

Consent is not a single signature, it’s a conversation that should continue for as long as you’re enrolled, and you have every right to ask for plain answers at any point along the way. That standard comes directly from FDA guidance, and it’s one we think every prospective participant deserves to hear clearly stated.

Educational resources exist to help patients navigate this exact decision, built for real questions, not just legal boilerplate. Guides on informed consent, eligibility criteria, and insurance coverage for trial participants are available to fill gaps that a rushed consent meeting sometimes leaves behind.

None of this replaces a conversation with your own treating clinician, who knows your history and can weigh a specific trial against your specific situation in ways a general guide cannot. Use these resources to walk into that conversation better prepared, with sharper questions and a clearer sense of what to expect.

Author perspective: a calm summary for decision-making

The honest picture is this: phase 1 trials carry a measured risk profile, not a reckless one. Mild and moderate side effects are common and expected. Severe outcomes are uncommon in the published data, and the safeguards behind dose escalation, stopping rules, and independent oversight exist precisely because uncertainty is real in early research, not eliminated by good intentions alone.

If you’re weighing a phase 1 trial, work through the consent checklist above, bring your questions to your treating clinician, and use resources like HCRF’s guides to fill in what a consent meeting alone might not cover. What follows are the sources behind these numbers, and a few common questions answered directly.

— HCRF

HCRF support and how to connect

Cancer research moves forward because people choose to fund the projects too new, too unproven, or too far outside convention for traditional grants to touch. A nonprofit foundation exists to back exactly that kind of work at a major comprehensive cancer center, supporting research that often becomes tomorrow’s phase 1 trial.

Hcrfwingstocure

If this article helped you understand what you or a loved one might be walking into, consider joining us at Cocktails for a Cure or HCRF’s 13th Annual Wings To Cure Gala, two evenings built around one shared purpose: funding the research that gives patients more trials worth considering in the first place.

FAQ

What happens during a phase 1 drug trial?

A phase 1 trial tests a new drug’s safety, tolerability, and dosing in a small group of people, usually starting with a conservative dose and increasing it gradually across cohorts. Participants undergo frequent monitoring, including blood tests, vital signs, and sometimes ECGs, so researchers can catch side effects early and adjust the dose accordingly.

How long does a phase 1 trial last?

The length varies by drug and design, but most phase 1 trials run from several months to about a year, factoring in dose-escalation cohorts and follow-up visits. Cellular and gene therapy trials often require longer follow-up periods, sometimes extending years beyond the last dose, because their effects can appear later.

What is the difference between a phase 1, 2, and 3 clinical trial?

Phase 1 trials focus on safety and dosing in a small group, phase 2 trials test whether the drug shows early signs of working in a larger group while continuing to monitor safety, and phase 3 trials compare the drug against standard treatment in much larger populations to confirm effectiveness and monitor for less common side effects. Our clinical trial phases guide breaks down each stage in more detail.

How many patients are in a phase 1 trial?

Sizes vary widely, but many cancer phase 1 studies enroll roughly 15 to 30 people, depending on how many dose levels the design requires. Trials with healthy volunteers, drawing on a broader systematic review of 475 trials totaling 27,185 participants, can range from a handful of people to several dozen depending on the drug being studied.

When 5% Matters: DAF vs Private Foundation for U.S. HNW Families
When 5% Matters: DAF vs Private Foundation for U.S. HNW Families
September 12, 2026

For U.S. high net worth families: compare DAFs and private foundations: tax limits, the 5% payout, privacy vs control, and when to use both.

Read More →